Fresh analysis suggests that people who stop using popular weight-loss injections like Wegovy and Mounjaro may regain reduced body mass far faster than those who end conventional lifestyle programs.
Published data in a major health publication points out that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"Individuals buying these drugs should be aware of the potential of rapid rebound weight gain when the medication concludes," warns researcher Dr. Susan Jebb.
That rate of regain means a reversion to starting mass within about 18 months.
Analyzing Treatments
The research, which reviewed dozens of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through lifestyle changes alone typically have a less rapid creep back—perhaps 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Experts propose the mode of action of the injections is key to understanding the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in appetite is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts argue that, considering the significant potential of weight regain, the therapy is often ongoing.
This opinion is supported by pharmaceutical companies, who state that the findings "emphasize the long-term character of obesity," similar to managing conditions like hypertension.
User Testimonies
People who have discontinued the jabs report a intense return of appetite.
"It was like something activating and you become starving," described one woman.
This difficulty is exacerbated if users have not developed sustainable dietary or behavioural changes during treatment.
Growing Adoption
Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone fix and long-term success likely depends on ongoing lifestyle management.
